Neurocrine Biosciences NBIX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $274.5M-61.9% | $721M+107% | $348.2M+28.0% | $272M+34.6% | $202.1M-16.1% | ||
| $1.05B+36.8% | $767.4M-0.9% | $774.6M+8.9% | $711.6M-5.0% | $749.4M-11.1% | ||
| $2.44B-3.4% | $2.52B+16.9% | $2.16B+23.4% | $1.75B+6.8% | $1.64B-5.0% | ||
| $90.9M+1.2% | $89.8M-7.7% | $97.3M+6.1% | $91.7M+5.4% | $87M+5.3% | ||
| $4.91B+5.9% | $4.63B+8.6% | $4.27B+9.7% | $3.89B+5.5% | $3.69B-0.8% | ||
| $773M+14.6% | $674.3M+15.4% | $584.3M+19.4% | $489.5M+3.0% | $475.2M+2.9% | ||
| $831.7M+11.9% | $743.4M+16.5% | $638M+16.8% | $546.3M+4.5% | $522.9M+3.0% | ||
| $1.5B+8.7% | $1.38B+9.2% | $1.26B+5.6% | $1.2B+3.8% | $1.15B+2.0% | ||
| 220M0.0% | 220M0.0% | 220M0.0% | 220M0.0% | 220M+219,900% | ||
| $589.6M+31.7% | $447.7M+52.3% | $294M+248% | $84.5M+1,694% | -$5.3M-118% | ||
| $3.41B+4.7% | $3.25B+8.3% | $3B+11.5% | $2.69B+6.3% | $2.54B-2.1% | ||
| $4.91B+5.9% | $4.63B+8.6% | $4.27B+9.7% | $3.89B+5.5% | $3.69B-0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Neurocrine Biosciences's total assets?
- Neurocrine Biosciences (NBIX) holds $4.9B in total assets, up 33.0% year over year.
- How much debt does Neurocrine Biosciences have?
- Neurocrine Biosciences carries $463.5M in total debt against $3.4B of shareholders' equity, a debt-to-equity ratio of 0.14.
- How much cash does Neurocrine Biosciences have?
- Neurocrine Biosciences holds $274.5M in cash and equivalents.
- Can Neurocrine Biosciences cover its short-term obligations?
- Its current ratio is 2.93 — current assets exceed current liabilities.
- Where does Neurocrine Biosciences's balance sheet data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
